NanoDimension
VC Fund
Grand Cayman, Cayman Islands
NanoDimension is a leading venture capital firm investing in disruptive technologies in and at the convergence of the life and physical sciences. We focus on early stage opportunities in the US and Europe led by exceptional entrepreneurs. NanoDimension’s investment team takes an active approach to building portfolio companies, leveraging ourexpertise and network to find and build companies with innovative solutions to critical global problems.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 36%
- Fund size:
- $335M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries NanoDimension invests in
Stages NanoDimension invests in
Countries NanoDimension invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 11 (26%)
- Health Care 9 (21%)
- Life Science 4 (10%)
- Therapeutics 4 (10%)
- Pharmaceutical 4 (10%)
Stage
- Series B 10 (24%)
- Series C 9 (21%)
- Series D 6 (14%)
- Funding Round 5 (12%)
- Series A 3 (7%)
Country
- United States 17 (40%)
- Switzerland 2 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jonathan Nicholson
Director
|
Director | Total investments: 0 | Find email | |
Aymeric Sallin
Founder and CEO
|
Founder and CEO | Total investments: 21 | Find email | |
Colin Walsh
Vice President
|
Vice President | Total investments: 13 | Find email | |
Eric Moessinger
Partner
|
Partner | Total investments: 22 | Find email | |
Kirill Kuzmichev
Principal
|
Principal | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Icosavax
|
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, whichit believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. | $100M / Series B / Apr 07, 2021 | |
Natron Energy
|
Natron Energy is an energy storage company that develops a high power, long cycle life, and low-cost battery technology. Natron’s battery products are based on a unique Prussian blue chemistry and can integrate into a wide variety of energy storage applications ranging from critical backup power systems to EV fast charging and behind-the-meterapplications. | $35M / Series D / Jul 08, 2020 | |
SQZ Biotech
|
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $65M / Series D / May 18, 2020 | |
Arctos Medical
|
Arctos Medical is a spin-off company from the University of Bern and has developed a revolutionary gene therapy that does not correct rare genetic eye diseases but much more common cases of blindness. | $9.3M / Seed / Dec 18, 2019 | |
|
Icosavax
|
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, whichit believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. | $51M / Series A / Oct 03, 2019 | |
Amphivena Therapeutics
|
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, andenhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing.It was founded in 2012 and is headquartered in South San Francisco, California. | $62M / Series C / Sep 24, 2019 | |
Inscripta
|
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $20M / Series C / Apr 04, 2019 | |
|
Inscripta
|
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $30M / Series C / Dec 19, 2018 | |
|
SQZ Biotech
|
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $72M / Series C / Aug 08, 2018 | |
Serotiny
|
Serotiny partners with leaders in the life sciences to make better therapies and tools by designing multi-domain proteins with novel functionality. They tailor protein designs for unique demands including treatment of cancers and genetic disorders. | $3M / Seed / Jul 10, 2018 | |
| See all 42 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does NanoDimension invest in?
NanoDimension invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series C stage. Most of the 42 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact NanoDimension?
Public channels for NanoDimension include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NanoDimension?
The team at NanoDimension includes Jonathan Nicholson (Director), Aymeric Sallin (Founder and CEO) and Colin Walsh (Vice President), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
